drugset / Trial / NCT02429687
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Phase 3
Recruiting
129 enrolled
Beihua Kong
Huazhong University of Science and Technology · collabSun Yat-sen University · collabZhejiang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian germ cell tumor patients after surgery.
Timeline
- Start
- 2015-04
- Primary completion
- 2025-05
- Completion
- 2030-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bleomycin | Unknown | 30000 iu | Intramuscular |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 20 mg/m2 | Intravenous |
| Comparator | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |